Bioventus Inc. (NASDAQ: BVS) reported Q3 EPS of ($0.07), $0.09 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $139 million versus the consensus estimate of $133.24 million.

GUIDANCE:

Bioventus Inc. sees FY2024 EPS of $0.40-$0.42, versus the consensus of $0.39. Bioventus Inc. sees FY2024 revenue of $562-567 million, versus the consensus of $561.7 million.

For earnings history and earnings-related data on Bioventus Inc. (BVS) click here.